Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
Clinical trial NCT07157306 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07157306
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-10
- Primary completion
- 2027-01-01
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.